BRIEF published on 04/07/2026 at 07:05, 1 month 22 days ago Aelis Farma obtient une subvention de 458 000 € pour son programme de lutte contre l'obésité France 2030 Aelis Farma Récepteur CB1 Recherche Sur L'obésité Subvention De Nouvelle-Aquitaine
BRIEF published on 04/07/2026 at 07:05, 1 month 22 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 1 month 22 days ago Informations privilégiées / Autres communiqués Aelis Farma reçoit 458 k€ de subvention de France 2030 en Nouvelle-Aquitaine pour son programme innovant dans l'obésité et les maladies métaboliques. Soutien non dilutif pour la recherche sur les traitements des désordres métaboliques Subvention France 2030 Obésité Aelis Farma Nouvelle-Aquitaine
PRESS RELEASE published on 04/07/2026 at 07:00, 1 month 22 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 2 months 8 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
BRIEF published on 03/21/2026 at 10:10, 2 months 8 days ago Aelis Farma fait progresser son essai clinique de phase 2B pour le traitement du syndrome de Down Essai Clinique AEF0217 Syndrome De Down Récepteur CB1 Comportement Adaptatif
PRESS RELEASE published on 03/21/2026 at 10:05, 2 months 8 days ago Informations privilégiées / Autres communiqués Aelis Farma lance avec succès l'étude clinique de Phase 2B avec AEF0217 pour traiter les troubles comportementaux et cognitifs du syndrome de Down. Recrutement actif en France, Italie et Espagne Phase 2b Étude Clinique Aelis Farma AEF0217 Syndrome De Down
PRESS RELEASE published on 03/21/2026 at 10:05, 2 months 8 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 4 months 17 days ago Aelis Farma obtient un avis favorable de l'EMA pour AEF0217 dans la trisomie 21 EMA Aelis Farma Trisomie 21 AEF0217 Développement Pédiatrique
BRIEF published on 01/12/2026 at 07:35, 4 months 17 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
Published on 05/29/2026 at 15:50, 5 hours 13 minutes ago Power Metallic Mines Announces Upsize of Brokered LIFE Offering for Gross Proceeds of up to C$30 Million
Published on 05/29/2026 at 14:30, 6 hours 33 minutes ago Sarama Completes Tranche 1 Equity Placement and ASX Cleansing Notice
Published on 05/29/2026 at 14:30, 6 hours 33 minutes ago Unusual Machines to Participate in June Investor Conferences
Published on 05/29/2026 at 14:20, 6 hours 43 minutes ago Ansell Announces Greenovation(TM) Awards for Sustainability Leadership and Waste Reduction
Published on 05/29/2026 at 13:59, 7 hours 4 minutes ago AIP Realty Trust Announces First Quarter 2026 Results
Published on 05/29/2026 at 20:00, 1 hour 3 minutes ago Brödernas publishes quarterly report for Jan-Mar 2026
Published on 05/29/2026 at 19:46, 1 hour 17 minutes ago CPI PROPERTY GROUP publishes financial results for the first quarter of 2026
Published on 05/29/2026 at 19:27, 1 hour 35 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/29/2026 at 19:18, 1 hour 45 minutes ago EQS-Adhoc: Ludwig Beck am Rathauseck-Textilhaus Feldmeier AG: Change to the shareholding structure
Published on 05/29/2026 at 18:50, 2 hours 13 minutes ago EQS-Adhoc: fox e-mobility AG: Capital Increase and Debt Reduction at Fox Automotive Switzerland AG – Adjustment of Shareholding Value – Departure of Philippe Perret – Financial Reports – Annual General Meeting D
Published on 05/29/2026 at 18:00, 3 hours 3 minutes ago Recticel Group versnelt groei in isolatiepanelen met geïntegreerde isothermische oplossingen na overname Isopanel NV
Published on 05/29/2026 at 18:00, 3 hours 3 minutes ago Recticel Group acquires Isopanel NV to deliver integrated solutions in the cold storage panels market
Published on 05/29/2026 at 15:38, 5 hours 25 minutes ago Déclaration d'actions et de droits de vote au 30.04.2026
